Close Menu

J&J

A group of Australian researchers has identified a set of plasma proteins that could help predict patient levels of the Alzheimer's disease-associated molecule beta-amyloid.

NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research said today that it will collaborate with Johnson & Johnson company Janssen to conduct clinical trials aimed at identifying new prostate cancer biomarkers.

As a first step into whole-genome sequencing, a division of Johnson & Johnson is sequencing 450 rheumatoid arthritis patients from a clinical trial of its approved drug Simponi (golimumab) with the goal of identifying disease predisposition genes and markers that correlate wi

NEW YORK (GenomeWeb News) – Veridex announced this week a deal with Laboratory Corporation of America to make its CellSearch circulating tumor cell test available in China.

Australian molecular diagnostics and research tools firm SpeeDx has published research demonstrating how its proprietary class of nucleic acid enzymes, called MNAzymes, can be used in combination with standard qPCR reagents to enable easy, inexpensive development of highly sensit

NEW YORK (GenomeWeb News) – Chinese regulators approved Veridex's CellSearch circulating tumor test for aiding in the diagnosis of women with metastatic breast cancer, Veridex announced on Wednesday.

Nanosphere has appointed Roy Davis to its board of directors. Davis worked for Johnson & Johnson for nearly three decades before he retired this January.

Despite its relatively low profile since it kicked off its third phase last spring, the Broad Institute's RNAi Consortium is proceeding apace, although its mission has expanded beyond its initial focus of just RNAi.

NEW YORK (GenomeWeb News) – Everist Genomics today said that it will open a lab within Johnson & Johnson's Janssen Labs innovation center in San Diego.

Protein biomarker diagnostics firm Astute Medical this week said it had completed a Series C financing round that raised $40.4 million.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.